ArticleMedical science monitor : international medical journal of experimental and clinical research2016
DNM3 Attenuates Hepatocellular Carcinoma Growth by Activating P53.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.Journal of translational medicine · 2022Article
- Exosomal microRNA-23a-3p contributes to the progression of cholangiocarcinoma by interaction with Dynamin3.Bioengineered · 2022Article
- Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer.Frontiers in molecular biosciences · 2022Article
- Expression of DNM3 is associated with good outcome in colorectal cancer.Open medicine (Warsaw, Poland) · 2022Article
- Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.The EMBO journal · 2021Article
- Review
- Dynamin 3 overexpression suppresses the proliferation, migration and invasion of cervical cancer cells.Oncology letters · 2021Article
- LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11.Cancer cell international · 2021Article
- Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer.International journal of general medicine · 2021Article
- Article
- Review
- The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of ABCF2 in hepatocellular carcinoma.Molecular oncology · 2020Article
- Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.Oncotarget · 2019Article
- Regulation of miRNAs by Snail during epithelial-to-mesenchymal transition in HT29 colon cancer cells.Scientific reports · 2019Article
- siPRDX2-elevated DNM3 inhibits the proliferation and metastasis of colon cancer cells via AKT signaling pathway.Cancer management and research · 2019Article
- Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis.Cancer management and research · 2019Article
- Construction of a recombinant eukaryotic expression vector containingOncoTargets and therapy · 2018Article
- DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme.Therapeutic advances in medical oncology · 2017Article
- Distinct functions of dynamin isoforms in tumorigenesis and their potential as therapeutic targets in cancer.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hepatocellular carcinoma is one of the most common malignant tumors in China and its mortality rate shows no sign at present of ceasing to rise. In our previous study, we found that the mRNA level of Dynamin3 (DNM3), a member of the Dynamin family, is significantly lower in hepatocellular carcinoma tissues than in non-tumor tissues. The aim of this study was to investigate the expression pattern and potential function of DNM3 in hepatocellular carcinoma. MATERIAL/
methodsFirst, we determined the expression ofDNM3 in human hepatocellular carcinoma tissues and cell lines. We then studied the biological function of DNM3 on hepatocellular carcinoma cells by proliferation assay and colony formation assay. Flow cytometry was used to study the effect of DNM3 on cell cycle and apoptosis.
resultsExpression of DNM3 was significantly downregulated in hepatocellular carcinoma tissues and was associated with vein invasion and tumor metastasis. In addition, upregulation of DNM3 reduced hepatocellular carcinoma cell proliferation and colony formation, induced hepatocellular carcinoma cell G0/G1 phase arrest, and stimulated hepatocellular carcinoma cell apoptosis. We also found that DNM3 may exert its anti-proliferative effect through upregulating p53.
conclusionsOur findings suggest that DNM3 attenuates the proliferation and induces apoptosis of gastric cancer cells. Modulation of DNM3 may prove to be an efficient method of hepatocellular carcinoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.